Dalzanemdor (SAGE-718), a novel, investigational N-methyl-D-aspartate receptor positive allosteric modulator: Safety, tolerability, and clinical pharmacology in randomized dose-finding studies in healthy participants and an open-label study in participants with Huntington's disease
Dalzanemdor (SAGE-718) 是一种新型的在研 N-甲基-D-天冬氨酸受体正向变构调节剂：在健康受试者中进行的随机剂量探索研究和在亨廷顿病患者中进行的开放标签研究中，评估其安全性、耐受性和临床药理学特性。
期刊:Cts-Clinical and Translational Science
影响因子:2.8
doi:10.1111/cts.13852
Koenig, Aaron; Lewis, Michael; Wald, Jeff; Li, Sigui; Varoglu, Mustafa; Dai, Jing; Sankoh, Abdul; Paumier, Katrina; Doherty, James; Quirk, Mike
